Congratulations to our customer Dexcom on today’s launch of the Dexcom G7 15-Day CGM System for adults 19 and up with diabetes. Their innovative approach empowers people with diabetes to live with more clarity and confidence. Learn more at the link below.
Building on the performance of Dexcom’s biosensing technology, we are excited to announce the upcoming launch of Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes in the United States. Starting Dec. 1, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. Dexcom G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services. Dexcom G7 15 Day is designed to provide real-time glucose readings for an industry-leading 15.5 days*† and continues to evolve Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range, and serves as a significant advancement in glucose management for people with diabetes. Click the link to learn more about Dexcom G7 15 Day: https://lnkd.in/duAT4aij * A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. †Excludes implantable CGM systems.
